Combining Surgery and Pembrolizumab for Lung Cancer Treatment
Author Information
Author(s): Gu Linguo, Chen Hongzuo, Xia Zhenkun, Qing Bei, Yuan Yunchang
Primary Institution: Department of Thoracic Surgery, Second Xiangya Hospital, Central South University, Changsha, China
Hypothesis
Can a combination of surgery and pembrolizumab improve outcomes for patients with pulmonary large cell carcinoma?
Conclusion
The combination of surgical resection and pembrolizumab treatment led to significant regression of the cancer and a progression-free status for the patient.
Supporting Evidence
- The patient was diagnosed with stage IIIA pulmonary large cell carcinoma.
- After surgery, the patient experienced tumor recurrence but responded well to pembrolizumab treatment.
- The patient remained progression-free after 24 cycles of pembrolizumab.
Takeaway
A patient with a rare type of lung cancer had surgery and then received a medicine called pembrolizumab, which helped shrink the cancer and keep it from coming back.
Methodology
The patient underwent surgical resection followed by adjuvant chemotherapy and pembrolizumab treatment.
Limitations
This is a single case report, and results may not be generalizable to all patients with pulmonary large cell carcinoma.
Participant Demographics
56-year-old male smoker
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website